selected publications
-
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management.
Blood advances.
2020
Academic Article
GET IT
Times cited: 112 -
Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2018
Academic Article
GET IT
Times cited: 205 -
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
Cancer discovery.
2018
Academic Article
GET IT
Times cited: 626 -
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
The New England journal of medicine.
2018
Academic Article
GET IT
Times cited: 1935 -
Disease characteristics and clinical outcomes in patients aged less than 40 with chronic lymphocytic leukemia.
Leukemia research.
2018
Academic Article
GET IT
Times cited: 2 -
Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2017
Academic Article
GET IT
Times cited: 12 -
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Leukemia research.
2016
Academic Article
GET IT
Times cited: 18 -
Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia.
British journal of haematology.
2016
Academic Article
GET IT
Times cited: 27 -
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.
Blood.
2016
Information Resource
GET IT
Times cited: 322 -
Hairy cell leukemia: Past, present and future.
Best practice & research. Clinical haematology.
2015
Information Resource
GET IT
Times cited: 14 -
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
The New England journal of medicine.
2015
Academic Article
GET IT
Times cited: 269 -
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center.
British journal of haematology.
2015
Academic Article
GET IT
Times cited: 14 -
CD19 CAR Therapy for Acute Lymphoblastic Leukemia.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
2015
Information Resource
GET IT
Times cited: 32 -
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.
Science translational medicine.
2014
Academic Article
GET IT
Times cited: 107 -
CD28z CARs and armored CARs.
Cancer journal (Sudbury, Mass.).
2014
Information Resource
GET IT
Times cited: 80 -
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Science translational medicine.
2014
Academic Article
GET IT
Times cited: 2060 -
Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2014
Academic Article
GET IT
Times cited: 73 -
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.
International journal of hematology.
2013
Information Resource
GET IT
Times cited: 91 -
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death.
Leukemia research.
2013
Academic Article
GET IT
Times cited: 65 -
Cellular therapies in acute lymphoblastic leukemia.
Hematology/oncology clinics of North America.
2011
Information Resource
GET IT
Times cited: 12 -
Curing all patients with acute promyelocytic leukemia: are we there yet?.
Hematology/oncology clinics of North America.
2011
Information Resource
GET IT
Times cited: 18 -
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.
Blood.
2011
Academic Article
GET IT
Times cited: 1112 -
Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible?.
Expert review of hematology.
2011
Information Resource
GET IT
Times cited: 8 -
Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy.
Oncology (Williston Park, N.Y.).
2011
Information Resource
GET IT
Times cited: 27 -
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.
Blood.
2011
Academic Article
GET IT
Times cited: 328 -
Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells.
Discovery medicine.
2010
Academic Article
GET IT
Times cited: 53